Expert Review of Anticancer Therapy

Article	Citations
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	75
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	66
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	38
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia	34
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	27
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs	24
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	24
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	24
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	24
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy	23
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	22
Progress in the development of tissue-based biomarkers for urothelial cancer	21
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma	21
Progress in histology specific treatments in soft tissue sarcoma	21
Current management of familial adenomatous polyposis	19
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	17
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	17
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	17
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma	17
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	16
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	15
Early detection of hepatocellular carcinoma: roadmap for improvement	15
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	14
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	14
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	14

The trend toward more target therapy in pancreatic ductal adenocarcinoma	13
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis	13
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	13
Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19th century	13
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	12
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	12
Deciding individual treatment for primary retroperitoneal sarcoma	12
Current status of robotic surgery for hepato-pancreato-biliary malignancies	12
Targeting GPRC5D in multiple myeloma	11
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	11
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?	11
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer	11
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer	11
Management of breast cancer diagnosed during pregnancy: global perspectives	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	10
Advances in systemic therapy for the first-line treatment of unresectable HCC	10
Nivolumab plus ipilimumab in malignant pleural mesothelioma	10
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	10
Novel breakthroughs in advanced prostate cancer management	10
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	10
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	9
Emerging treatment options for prostate cancer	9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	9
Pembrolizumab in the first-line treatment of advanced head and neck cancer	9
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	9
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	9
Benign and malignant cardiac masses: long-term outcomes after surgical resection	9
Interventions to reduce the risk of side-effects of cancer treatments in childhood	9
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	9
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	8
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	8
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)	8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	8
Oligometastases in head and neck squamous cell carcinoma patients	8
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	8
Molecular-driven treatment for biliary tract cancer: the promising turning point	8
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	8
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty	8
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy	8
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy	8
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	7

The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	7
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	7
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	7
How can we better distinguish metastatic tumors from primary tumors in the breast?	7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	7
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials	7
Cemiplimab for locally advanced and metastatic basal cell carcinoma	7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	7
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	7
The optimal management of brain metastases from gestational trophoblastic neoplasia	6
Venetoclax and beyond: New Horizons in CLL and AML therapy	6
Circadian rhythm-based cancer therapy in randomised clinical trials	6
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	6
Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium	6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	6
Immune checkpoint inhibition in early-stage triple-negative breast cancer	6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	6
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	6
Primary site and treatment impact in unresectable metastatic colorectal cancer	6
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	6
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	6
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	6
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	6
Real-world experience with trabectedin for the treatment of recurrent ovarian cancer	6
Medullary thyroid carcinoma: a narrative historical review	6
Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	5
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	5
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	5
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	5
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
The role of planetary health in urologic oncology	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	5
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	5
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?	5
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	5
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma	5
Surgical management of intrahepatic cholangiocarcinoma	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	5
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	5
Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer	5
How can we mitigate treatment-associated morbidity in patients with germ cell tumors?	5
Relugolix in the management of prostate cancer	5
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	4
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	4
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	4
How can we address the challenge of distant metastases in HNSCC prognosis?	4
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens	4
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	4
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma	4
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database	4
Advances and future directions in radiopharmaceutical delivery for cancer treatment	4
Desmoplastic small round cell tumor: from state of the art to future clinical prospects	4
Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges	4
Clear cell sarcoma: state-of-the art and perspectives	4
Current and emerging treatment options for BRAFV600-mutant melanoma	4
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	4
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity	4
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches	4
The multidisciplinary management of locally advanced rectal cancer	4
Therapeutic options in thymomas and thymic carcinomas	4
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	4
The effect of mechanical force in genitourinary malignancies	4
Immune checkpoint inhibitors for recurrent endometrial cancer	4

Cancer immunotherapy efficacy and machine learning	4
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	4
Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis	4
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment	4
Factors influencing survival in metastatic castration-resistant prostate cancer therapy	4
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care	4
Combined endocrine and targeted therapy in luminal breast cancer	4
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review	3
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management	3
Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based stud	3
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer	3
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis	3
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	3
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized cont	3
How can we create precision immunotherapy as standard in breast cancer?	3
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis	3
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma	3
Implementing machine learning to predict survival outcomes in patients with resected pulmonary large cell neuroendocrine carcinoma	3
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?	3
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis	3
Avelumab in locally advanced or metastatic urothelial carcinoma	3
Hot topics in renal cancer pathology: implications for clinical management	3
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges	3
Understanding the link between aspartame and cancer	3
Treatment of cervical cancer: overcoming challenges in access to brachytherapy	3
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis	3
How do non-coding RNAs impact treatment regimens currently being used in AML?	3
Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database	3
Repurposing antipsychotic drugs for cancer treatment: current evidence and future perspectives	3
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions	3
Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management	3
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors	3
A meta-analysis of UCA1 accuracy in the detection of bladder cancer	3
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	3
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis	3
Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma	3
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma	3
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer	3
Targeted therapies in advanced biliary malignancies: a clinical review	3
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy	3
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial	3
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review	2
Melanoma neoadjuvant treatment: review and update of recent trials	2
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer	2
Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment?	2
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement	2
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy	2
2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma	2
Novel therapies for metastatic prostate cancer	2
Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives	2
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin	2
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	2
Diagnostic accuracy of diffusion-weighted imaging in differentiating glioma recurrence from posttreatment-related changes: a meta-analysis	2
Re-irradiation for recurrent/progressive pediatric brain tumors: from radiobiology to clinical outcomes	2
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab	2
20 years of Expert Review of Anticancer Therapy	2
Myeloid cell leukemia-1 as a candidate prognostic biomarker in cancers: a systematic review and meta-analysis	2
A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022	2
Medullary thyroid carcinoma	2
Low CBS expression can identify patients who benefit from adjuvant chemotherapy in gastric cancer	2
Integrating supportive care into the multidisciplinary management of lung cancer: we can’t wait any longer	2
Targeting the DNA damage response in pediatric malignancies	2
Future investigative directions for novel therapeutic targets in head and neck cancer	2
Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma	2
Current usage of pembrolizumab in triple negative breast cancer (TNBC)	2
Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy	2
Increasing the accuracy of colorectal cancer screening	2
Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma	2
Locoregional recurrence in triple negative breast cancer: past, present, and future	2
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment	2
Diagnostic accuracy of arterial spin labeling in differentiating between primary central nervous system lymphoma and high-grade glioma: a systematic review and meta-analysis	2
Overview and recent advances in incidental meningioma	2
Current androgen receptor antagonists under investigation for resistant prostate cancer	2
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a system	2
Contemporary management of diffuse large B-cell lymphoma in Japan	2
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer	2
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes	2
Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma	2
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors	2
Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity	2
Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics	2
Challenges in the combination of radiotherapy and immunotherapy for breast cancer	2
The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis	2
Immunosenescence, inflammaging, and cancer immunotherapy efficacy	2
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies	2
High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes	2
The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and/or right atrium: a systematic review and single-arm meta-analysis	2
Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis	2
Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?	2
Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer	2
Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives	2
Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis	2
The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research	2